Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 16/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128198 | 0.89 | ALDH1A1 (0.47) | NPY2RMAPTLMNA | |
| SCHEMBL5137278 | 0.81 | NPY2R (0.39) | NPY2RDPP4DPP7LMNA | |
| SCHEMBL5084608 | 0.79 | NPY2R (0.54) | NPY2R | |
| SCHEMBL3659972 | 0.78 | KMT2A (0.55) | NPY2RMAPTKMT2AMEN1LMNA | |
| SCHEMBL5083849 | 0.78 | NPY2R (0.46) | NPY2R | |
| SCHEMBL7605106 | 0.78 | NPY2R (0.68) | NPY2RMAPTKMT2AMEN1 | |
| SCHEMBL7602201 | 0.78 | NPY2R (0.68) | NPY2RMAPTKMT2AMEN1 | |
| SCHEMBL5080939 | 0.76 | NPY2R (0.75) | NPY2R | |
| SCHEMBL5083826 | 0.76 | NPY2R (0.69) | NPY2RMAPTKMT2AMEN1LMNA | |
| SCHEMBL5083776 | 0.72 | NPY2R (0.69) | NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | claimed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | NPY2R 1/4885MAPT 4559/4885DPP4 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.